男女猛烈激情XX00免费视频,办公室奶边摸边做爰视频,野花影院手机在线观看免费6

Release date：2019-09-23

JACI

[IF:13.1]

Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a 1
https://doi.org/10.1016/j.jaci.2019.02.029
Background: There have been few studies conducted on the efficacy and safety of specific immunotherapy with allergen extracts of fungi compared with other allergen extracts, and there are no data on the major allergen Alt a 1 of the fungus Alternaria alternata.
Objectives: We sought to evaluate the efficacy and safety of subcutaneous immunotherapy with 2 different doses of Alt a 1 in patients with rhinoconjunctivitis caused by sensitization to A alternata.
Method: We performed a multicenter, randomized, double- blind, placebo-controlled trial with Alt a 1 administered subcutaneously in patients with allergic rhinoconjunctivitis with or without controlled asthma aged 12 to 65 years. Three groups were included: the placebo group and active groups receiving
0.2 or 0.37 mg of Alt a 1 per dose. The main end point was the combined symptom and medication score. Secondary end points were cutaneous reactivity and serum IgE and IgG4 levels to Alt a 1. Recorded adverse reactions were graded according to World Allergy Organization criteria.
Results: There were significant reductions in the combined symptom and medication score for the 0.37-mg dose of Alt a 1 compared with placebo at 12 months of treatment. Reduced cutaneous reactivity and IgE levels, together with increased IgG4 levels, were demonstrated for the 2 active groups versus the placebo group. A similar safety profile was found for both active groups compared with the placebo group. No serious adverse drug reactions were reported.
Conclusion: Immunotherapy with Alt a 1 was efficacious and safe, reducing the symptoms and medication consumption associated with rhinoconjunctivitis after only 1 year of treatment. The clinical benefits were associated with reduced skin reactivity and specific IgE levels and increased IgG4 levels. (J Allergy Clin Immunol 2019;144:216-23.)
All Author:
Ana Isabel Tabar, MD, PhD, Luis Prieto, MD, PhD, Pilar Alba, MD,Antonio Nieto, MD, PhD,Mercedes Rodr'?guez, MD,
Miguel Torrecillas, MD,Beatriz Huertas, MD,Elisa Go'mez, MD, PhD, Francisco Javier Ferna'ndez, MD, PhD
Miguel Blanca, MD, PhD, David Rodr'?guez, PhD, and Ricardo Palacios, PhD
Pamplona, Valencia, Madrid, Albacete, Ciudad Real, Alicante, and Malaga, Spain

2019-9-3 Article

Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd. Copyright HZKC Technical support 浙ICP備14005341號(hào) （浙）-非經(jīng)營(yíng)性-2019-0050

Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist. Tel: 0571-87968248-805 Website:m.carnationgroup.cn

Official WeChat

日韩成人av免费电影,久久精品这里只有精品,午夜激情黄色大片网站,亚洲高清一区二区三区不卡av,国产精品久久久一级二级,天天干天天日天天操,国精品无码人妻一区二区三区,综合久久综合久久

杭州浙大迪迅生物基因工程有限公司

Release date：2019-09-23

日韩成人av免费电影,久久精品这里只有精品,午夜激情黄色大片网站,亚洲高清一区二区三区不卡av,国产精品久久久一级二级,天天干天天日天天操,国精品无码人妻一区二区三区,综合 久久 综合 久久

杭州浙大迪迅生物基因工程有限公司

Release date：2019-09-23

日韩成人av免费电影,久久精品这里只有精品,午夜激情黄色大片网站,亚洲高清一区二区三区不卡av,国产精品久久久一级二级,天天干天天日天天操,国精品无码人妻一区二区三区,综合久久综合久久